Education
About Us
Working with TipRanks
Follow Us
Botanix Pharmaceuticals Limited (AU:BOT)
ASX:BOT
RESEARCH TOOLSreports
BOT Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$0.54
Previous CloseN/A
Volume8.15M
Average Volume (3M)15.60M
Market Cap
AU$284.36M
Enterprise ValueAU$139.76M
Total Cash (Recent Filing)AU$48.44M
Total Debt (Recent Filing)AU$866.35K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 28, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,961,126,600
10 Day Avg. Volume26,140,088
30 Day Avg. Volume15,600,074
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)6.54
Price to Sales (P/S)0.00
P/FCF Ratio-7.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.00Price Target Upside1076.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Botanix Pharmaceuticals Limited News
PremiumCompany Announcements
Botanix Pharmaceuticals Updates Sofdra Prescription Metrics
PremiumCompany Announcements
Botanix Pharmaceuticals Announces Sofdra™ Launch Update
PremiumCompany Announcements
Botanix Pharmaceuticals Reports Strong Launch for Sofdra
PremiumCompany Announcements
Botanix Pharmaceuticals to Host Webinar on Sofdra’s Market Success
PremiumCompany Announcements
Botanix Pharmaceuticals Announces Cessation of Securities
PremiumCompany Announcements
Botanix Pharmaceuticals Announces Quotation of New Securities
Bulls Say, Bears Say
Bulls Say
Market DemandSofdra launch update underscores strong demand and sustained growth potential.
Revenue GrowthGross revenue from Sofdra more than doubled from February to March 2025, demonstrating strong initial market acceptance.
Sales GrowthStrong early sales of Sofdra are driven by a growing prescriber base and high patient adherence.
Bears Say
Competitive LandscapeThe market for PAH treatments is projected to grow significantly, offering a sizable opportunity for Sofdra.
Financial ProjectionsGross to Net indicators are tracking positively, contributing to its financial health.
Options Prices
Currently, No data available
---
Ownership Overview
1.35% Insiders
―
Mutual Funds
― Other Institutional Investors
98.63% Public Companies and Individual Investors
BOT FAQ
What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?
Botanix Pharmaceuticals Limited lowest share price was AU$0.13 and its highest was AU$0.54 in the past 12 months.
What is Botanix Pharmaceuticals Limited’s market cap?
Botanix Pharmaceuticals Limited’s market cap is AU$284.36M.
When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?
Botanix Pharmaceuticals Limited’s upcoming earnings report date is Aug 28, 2025 which is in 48 days.
How were Botanix Pharmaceuticals Limited’s earnings last quarter?
Botanix Pharmaceuticals Limited released its earnings results on Feb 25, 2025. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of AU$0.001 by -AU$0.018.
Is Botanix Pharmaceuticals Limited overvalued?
According to Wall Street analysts Botanix Pharmaceuticals Limited’s price is currently Undervalued.
Does Botanix Pharmaceuticals Limited pay dividends?
Botanix Pharmaceuticals Limited does not currently pay dividends.
What is Botanix Pharmaceuticals Limited’s EPS estimate?
Botanix Pharmaceuticals Limited’s EPS estimate is -0.01.
How many shares outstanding does Botanix Pharmaceuticals Limited have?
Botanix Pharmaceuticals Limited has 1,961,126,600 shares outstanding.
What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?
Botanix Pharmaceuticals Limited reported an EPS of -AU$0.017 in its last earnings report, missing expectations of AU$0.001. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:BOT
Botanix Pharmaceuticals Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$2.00 (1076.47% Upside)
AU$2.00 (1076.47% Upside)
Blogger Sentiment
Bullish
AU:BOT Sentiment 96%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.00%
12-Months-Change
Fundamentals
Return on Equity
-56.99%
Trailing 12-Months
Asset Growth
108.57%
Trailing 12-Months
Company Description
Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.
BOT Stock 12 Month Forecast
Average Price Target
AU$2.00
▲(1076.47%Upside)
Technical Analysis
Opthea Limited
―
Clinuvel Pharmaceuticals
―
Orthocell Ltd
―
Immutep Ltd
―
Dimerix Limited
―